{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-043821","form_type":"8-K","ticker":"PCSA","cik":"0001533743","company_name":"Processa Pharmaceuticals, Inc.","filed_at":"2024-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.718172+00:00","generated_at":"2026-05-30T04:30:55.729190+00:00","sec_items":["4.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Processa Pharmaceuticals replaces auditor BD & Co. with Cherry Bekaert","bullets":["BD & Co. resigned Oct 31, 2024 after merger into Citrin Cooperman; no disagreements or reportable events.","Audit Committee appointed Cherry Bekaert LLP for FY 2024 and subsequent interim periods.","No prior consultations with Cherry Bekaert regarding accounting principles or disagreements.","BD & Co.'s audit reports for 2023 and 2022 were unqualified and contained no adverse opinion."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-043821","json":"https://secwatch.observer/filing/0001493152-24-043821.json","markdown":"https://secwatch.observer/filing/0001493152-24-043821.md","text":"https://secwatch.observer/filing/0001493152-24-043821.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533743/000149315224043821/0001493152-24-043821-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533743/000149315224043821/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T04:30:55.729190+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}